We previously demonstrated that RMC exhibits a “hot” immune-inflamed phenotype characterized by upregulation of immune checkpoints such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) in the tumor immune microenvironment10. The gene discussed is CTLA4; the disease is neoplasm.